Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer

BMC Cancer

Research

Bin Liu¹  Lina Zhang¹  Li Tong²  Yi Guo³  Fei Qi⁴  Ying Wang⁴  Tongmei Zhang⁴  Baohua Lu⁴  Cong Zhao⁴  Baolan Li⁴  Yanxia Liu⁵  Zhiyun Zhang⁵ 

[1]Cancer research center, Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Beijing, China

[2]Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China

[3]Emergency Department, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, China

[4]General Department, Beijing Chest Hospital, Capital Medical University, 101149, Beijing, China

[5]General Department, Beijing Chest Hospital, Capital Medical University, 101149, Beijing, China

[6]Cancer research center, Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Beijing, China

关键词: Hepatocyte growth factor;    Plasma;    Pan-cancer analysis;    Small cell lung cancer;    Metastases;   

DOI  :  10.1186/s12885-023-10995-z

 received in 2022-11-10, accepted in 2023-05-22,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundHepatocyte growth factor (HGF) is a peptide-containing multifunctional cytokine, which is overexpressed and/or activated in multiple malignancies and is reported to be associated with tumor development and inferior survival. At present, the role of HGF in small cell lung cancer (SCLC) has not been fully explored yet.Materials and methodsThe expression of HGF and its value in predicting survival in SCLC were explored from GEO database and in pan-cancer analysis. Furthermore, we detected the expression of HGF using tumor tissue and paired plasma samples from a validation cohort of 71 SCLC patients at our institute. Correlation between tumor and plasma HGF expression and the prognostic values were analyzed.ResultsGEO database analysis revealed that tumor tissue had lower HGF expression than paired normal tissue in SCLC. At our institute, immunohistochemical staining showed negative expression of HGF in tumor tissue of SCLC at our institute (47/47, 100%). The average baseline plasma HGF was 1.28 (range,0.42–4.35) ng/ml. However, plasma HGF was higher in SCLC patients with patients with N3, M1, liver metastasis (LM) and bone metastasis (BM) disease compared with those N0 − 2 (1.25 vs. 1.75 ng/mL, P = 0.000), M0 (1.26 vs. 1.63 ng/mL, P = 0.003), non-LM (1.32 vs. 2.06 ng/mL, P = 0.009), and non-BM (1.35 vs. 1.77 ng/mL, P = 0.047), respectively. Multivariate analysis revealed plasma HGF was an independent predictor for LM and prognostic factor of OS.ConclusionOur results revealed that plasma HGF rather than tumor HGF exhibited a potential role in predicting metastasis and survival in SCLC. Plasma HGF might be used as a non-invasive detecting and monitoring tool for SCLC.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 1

Fig. 2

Fig. 5

Fig. 2